The FDA today approved the first new weight-loss drug for ordinary obese patients since 2014!

Today, the US FDA announced that it has approved the Wegovy (semaglutide, 2.

Obesity is a global epidemic, and with the improvement of people's living standards, its incidence continues to increase.

Smeglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which can stimulate the production of insulin, inhibit the secretion of glucagon, and reduce appetite and food intake.

The efficacy and safety of Wegovy were evaluated in 4 68-week STEP clinical trials.

▲Wegovy significantly reduced the weight of patients in 4 phase 3 clinical trials (picture source: Novo Nordisk official website)

Novo Nordisk has announced a few days ago that it will launch a key phase 3a clinical trial to test the weight loss effect of oral smeglutide.

The company's obesity research and development pipeline also has a subcutaneously injected amylin analogue AM833.

▲Simeglutide and AM833 control appetite through complementary mechanisms of action (picture source: Novo Nordisk official website)

In the phase 1 clinical trial, the highest dose of AM833 combined with simegliutide can reduce the patient’s body weight by 17.

▲The highest dose of AM833 as a single agent (left picture) or combined with smegaglutide (right picture), reduced the patient's weight by 10.

In addition to Wegovy, the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor dual agonist tirzepatide developed by Eli Lilly has achieved a significant reduction in glycated hemoglobin (A1C) in 5 phase 3 clinical trials for the treatment of patients with type 2 diabetes.

Note: The original text has been deleted

Reference materials:

[1] FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.